Evidence map›Paper›PMID 30733620›Full record

ArticleNature2019

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, Valesca Bukur, Stefan Stevanović, Cecile Gouttefangeas, Michael Platten, Ghazaleh Tabatabai, Valerie Dutoit, Sjoerd H van der Burg and 54 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Computational identification of cross-reactive TCR epitopes with ARDitox.Journal of cancer research and clinical oncology · 2025
    Article
  2. Anti-GM-CSF autoantibodies in myeloid leukemias.Best practice & research. Clinical haematology · 2025
    Review
  3. Review
  4. Identification of patient-specific CD4Nature biotechnology · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

64 authors.

Norbert Hilf *Immatics Biotechnologies GmbH, Tübingen, Germany.
Sabrina Kuttruff-Coqui *Immatics Biotechnologies GmbH, Tübingen, Germany.
Katrin FrenzelBioNTech AG, Mainz, Germany.
Valesca BukurBioNTech AG, Mainz, Germany.
Stefan StevanovićEberhard Karls Universität Tübingen, Tübingen, Germany.
Cecile GouttefangeasEberhard Karls Universität Tübingen, Tübingen, Germany.
Michael PlattenUniversity Hospital Heidelberg, Heidelberg, Germany.
Ghazaleh TabatabaiEberhard Karls Universität Tübingen, Tübingen, Germany.
Valerie DutoitGeneva University Hospital, Geneva, Switzerland.
Sjoerd H van der BurgCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Per Thor StratenCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Francisco Martinez-RicarteVall d'Hebron University Hospital, Barcelona, Spain.
Berta PonsatiBCN Peptides SA, Barcelona, Spain.
Hideho OkadaUniversity of California, San Francisco, San Francisco, CA, USA.
Ulrik LassenRinghospitalet, Copenhagen, Denmark.
Arie AdmonTechnion - Israel Institute of Technology, Haifa, Israel.
Christian H OttensmeierUniversity of Southampton, Southampton, UK.
Alexander UlgesImmatics Biotechnologies GmbH, Tübingen, Germany.
Sebastian KreiterBioNTech AG, Mainz, Germany.
Andreas von DeimlingUniversity Hospital Heidelberg, Heidelberg, Germany.
Marco SkardellyUniversity Hospital Tübingen, Tübingen, Germany.
Denis MiglioriniGeneva University Hospital, Geneva, Switzerland.
Judith R KroepLeiden University Medical Center, Leiden, The Netherlands.
Manja IdornCenter for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
Jordi RodonVall d'Hebron University Hospital, Barcelona, Spain.
Jordi PiroBCN Peptides SA, Barcelona, Spain.
Hans S PoulsenRinghospitalet, Copenhagen, Denmark.
Bracha ShraibmanTechnion - Israel Institute of Technology, Haifa, Israel.
Katy McCannUniversity of Southampton, Southampton, UK.
Regina MendrzykImmatics Biotechnologies GmbH, Tübingen, Germany.
Martin LowerBioNTech AG, Mainz, Germany.
Monika StieglbauerEberhard Karls Universität Tübingen, Tübingen, Germany.
Cedrik M BrittenBioNTech AG, Mainz, Germany.
David CapperUniversity Hospital Heidelberg, Heidelberg, Germany.
Marij J P WeltersCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Juan SahuquilloVall d'Hebron University Hospital, Barcelona, Spain.
Katharina KieselImmatics Biotechnologies GmbH, Tübingen, Germany.
Evelyna DerhovanessianBioNTech AG, Mainz, Germany.
Elisa RuschEberhard Karls Universität Tübingen, Tübingen, Germany.
Lukas BunseUniversity Hospital Heidelberg, Heidelberg, Germany.
Colette SongImmatics Biotechnologies GmbH, Tübingen, Germany.
Sandra HeeschBioNTech AG, Mainz, Germany.
Claudia WagnerImmatics Biotechnologies GmbH, Tübingen, Germany.
Alexandra Kemmer-BruckBioNTech AG, Mainz, Germany.
Jorg LudwigImmatics Biotechnologies GmbH, Tübingen, Germany.
John C CastleBioNTech AG, Mainz, Germany.
Oliver SchoorImmatics Biotechnologies GmbH, Tübingen, Germany.
Arbel D TadmorTRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany.
Edward GreenGerman Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
Jens FritscheImmatics Biotechnologies GmbH, Tübingen, Germany.
Miriam MeyerImmatics Biotechnologies GmbH, Tübingen, Germany.
Nina PawlowskiImmatics Biotechnologies GmbH, Tübingen, Germany.
Sonja DornerImmatics Biotechnologies GmbH, Tübingen, Germany.
Franziska HoffgaardImmatics Biotechnologies GmbH, Tübingen, Germany.
Bernhard RosslerImmatics Biotechnologies GmbH, Tübingen, Germany.
Dominik MaurerImmatics Biotechnologies GmbH, Tübingen, Germany.
Toni WeinschenkImmatics Biotechnologies GmbH, Tübingen, Germany.
Carsten ReinhardtImmatics Biotechnologies GmbH, Tübingen, Germany.
Christoph HuberBioNTech AG, Mainz, Germany.
Hans-Georg RammenseeEberhard Karls Universität Tübingen, Tübingen, Germany.
Harpreet Singh-JasujaImmatics Biotechnologies GmbH, Tübingen, Germany.
Ugur SahinBioNTech AG, Mainz, Germany.
Pierre-Yves DietrichGeneva University Hospital, Geneva, Switzerland.
Wolfgang WickUniversity Hospital Heidelberg, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.

Identifiers

PMID30733620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.